Wilson Disease: When Copper Becomes Toxic

Overview

Wilson disease, also known as hepatolenticular degeneration, is an inherited disorder of copper metabolism caused by mutations in the ATP7B gene. This results in defective copper transport, leading to toxic accumulation primarily in the liver and brain, but also affecting the eyes, kidneys, and other organs.

Named after Samuel Alexander Kinnier Wilson who described the condition in 1912, this disease represents one of the few genetic metabolic disorders that is completely treatable. However, the key to preventing irreversible damage lies in early diagnosis and prompt treatment initiation. Unfortunately, the disease's variable presentation often leads to diagnostic delays, sometimes with tragic consequences.

The copper accumulation begins at birth, but symptoms typically don't appear until copper levels reach toxic thresholds. This can occur anywhere from early childhood to late adulthood, making Wilson disease a great mimicker that can present as liver disease, neurological disorder, psychiatric illness, or a combination of these.

Why Copper Matters

Copper is an essential trace element required for:

• Energy production in cells
• Iron metabolism
• Connective tissue formation
• Neurotransmitter synthesis
• Antioxidant defense
• Immune function

However, free copper is highly toxic, generating reactive oxygen species that damage proteins, lipids, and DNA. The body normally maintains careful copper balance through complex regulatory mechanisms, which fail in Wilson disease.

Historical Milestones

• 1912: Wilson describes "progressive lenticular degeneration"
• 1948: Cumings demonstrates excess copper in brain and liver
• 1956: Walshe introduces penicillamine treatment
• 1969: Sternlieb and Scheinberg establish diagnostic criteria
• 1993: ATP7B gene identified
• 1997: Zinc therapy approved by FDA
• Present: Gene therapy trials underway

Genetics and Inheritance

Wilson disease follows an autosomal recessive inheritance pattern, requiring mutations in both copies of the ATP7B gene.

The ATP7B Gene

• Located on chromosome 13 (13q14.3)
• Encodes a copper-transporting P-type ATPase
• Over 900 mutations identified
• Most patients are compound heterozygotes (different mutations on each allele)
• Mutation type partially influences presentation

Inheritance Pattern

• Both parents carriers: 25% chance affected child
• Carrier frequency: 1 in 90 in general population
• Higher in certain populations:
  • Sardinia: 1 in 7
  • Costa Rica: 1 in 30
  • Japan: 1 in 30
  • Ashkenazi Jews: Increased frequency

Genotype-Phenotype Correlations

• H1069Q mutation: Most common in Europeans, later neurological onset
• R778L mutation: Common in Asians, hepatic presentation
• Truncating mutations: Earlier, more severe presentation
• Missense mutations: Variable presentation

Genetic Testing

• Direct mutation analysis: Can identify specific mutations
• Useful for:
  • Confirming diagnosis
  • Family screening
  • Prenatal diagnosis
  • Genetic counseling
• Limitations:
  • Many rare mutations
  • May miss novel mutations
  • Expensive and time-consuming

How Copper Becomes Toxic

Understanding the mechanism helps explain the diverse manifestations and treatment approaches.

Normal Copper Metabolism

1. Absorption: 1-2 mg daily from small intestine
2. Transport: Bound to albumin and amino acids to liver
3. Hepatic uptake: Via CTR1 transporter
4. Intracellular handling: Chaperone proteins deliver to targets
5. Incorporation: Into ceruloplasmin and other proteins
6. Excretion: Mainly via bile (2-3 mg daily)

Defects in Wilson Disease

• ATP7B dysfunction:
  • Cannot load copper onto ceruloplasmin
  • Cannot excrete copper into bile
• Consequences:
  • Hepatic copper accumulation
  • Low ceruloplasmin (lacks copper)
  • Overflow to other organs
  • Free copper toxicity

Mechanisms of Copper Toxicity

• Oxidative stress: Free radical generation
• Mitochondrial damage: Impaired energy production
• Protein dysfunction: Copper binding disrupts function
• DNA damage: Mutations and cell death
• Lipid peroxidation: Membrane damage
• Inflammation: Cytokine release

Organ-Specific Effects

• Liver: Steatosis → inflammation → fibrosis → cirrhosis
• Brain: Basal ganglia most vulnerable (movement control)
• Eyes: Descemet's membrane copper deposition
• Kidneys: Tubular dysfunction
• Heart: Cardiomyopathy (rare)
• Blood: Hemolysis from copper release

Clinical Presentations

Wilson disease is remarkably variable, leading to frequent misdiagnosis. Age and primary organ involvement determine presentation.

Age-Related Patterns

• Before age 5: Rare, usually asymptomatic
• 5-15 years: Predominantly hepatic
• 15-30 years: Mixed hepatic and neurological
• After 30: Often neuropsychiatric
• After 40: Unusual but possible

Hepatic Presentations (40-50%)

Asymptomatic Hepatomegaly

• Incidental finding
• Elevated transaminases
• May persist for years

Acute Hepatitis

• Mimics viral hepatitis
• Jaundice, malaise, anorexia
• May resolve spontaneously
• Can recur

Chronic Hepatitis

• Progressive liver disease
• Portal hypertension
• Cirrhosis development
• May be misdiagnosed as autoimmune

Fulminant Hepatic Failure

• Life-threatening presentation
• Usually young women
• Coombs-negative hemolytic anemia
• Very low alkaline phosphatase
• High bilirubin/alkaline phosphatase ratio
• Requires urgent transplantation

Neurological Presentations (40-50%)

Movement Disorders

• Tremor: "Wing-beating" or postural
• Dystonia: Abnormal postures
• Chorea: Involuntary movements
• Parkinsonism: Rigidity, bradykinesia
• Ataxia: Coordination problems

Other Neurological Signs

• Dysarthria (slurred speech)
• Dysphagia (swallowing difficulty)
• Drooling
• Gait abnormalities
• Seizures (rare)

Psychiatric Presentations (10-20%)

• Personality changes: Irritability, disinhibition
• Depression: Common initial symptom
• Anxiety disorders: Panic attacks, phobias
• Psychosis: Hallucinations, delusions
• Cognitive decline: Memory, attention deficits
• Behavioral problems: Especially in adolescents

Mixed Presentations

Many patients have combinations:

• Hepatic + neurological (most common)
• Neurological + psychiatric
• All three systems involved

Symptoms by System

Wilson disease can affect virtually every organ system, though liver and brain involvement dominate.

Hepatic Symptoms

• Early:
  • Fatigue
  • Abdominal discomfort
  • Hepatomegaly
  • Spider angiomas
• Progressive:
  • Jaundice
  • Ascites
  • Edema
  • Variceal bleeding
  • Hepatic encephalopathy

Neurological Symptoms

• Motor:
  • Tremor (50-60%)
  • Dystonia (30-40%)
  • Rigidity
  • Bradykinesia
  • Gait disturbance
• Speech/Swallowing:
  • Dysarthria (85% of neurological cases)
  • Dysphagia
  • Drooling
  • Facial grimacing

Psychiatric Symptoms

• Mood:
  • Depression (20-30%)
  • Mood swings
  • Emotional lability
• Behavioral:
  • Personality changes
  • Impulsivity
  • Aggression
  • Social withdrawal
• Cognitive:
  • Memory impairment
  • Executive dysfunction
  • Attention deficits
  • Academic decline

Ophthalmologic Signs

• Kayser-Fleischer rings:
  • Copper in Descemet's membrane
  • Green-brown ring at corneal periphery
  • Present in 95% with neurological symptoms
  • Present in 65% with hepatic symptoms
  • Requires slit-lamp examination
• Sunflower cataracts: Less common

Renal Manifestations

• Fanconi syndrome
• Renal tubular acidosis
• Aminoaciduria
• Glycosuria
• Hypercalciuria
• Nephrolithiasis

Hematologic Manifestations

• Hemolytic anemia:
  • Acute copper release
  • Coombs-negative
  • Can trigger diagnosis
• Thrombocytopenia: From hypersplenism
• Leukopenia: Less common

Other Manifestations

• Skeletal:
  • Osteoporosis
  • Osteomalacia
  • Arthritis
  • Spontaneous fractures
• Cardiac:
  • Cardiomyopathy (rare)
  • Arrhythmias
• Endocrine:
  • Hypoparathyroidism
  • Amenorrhea
  • Infertility

Diagnosis

Diagnosis requires a combination of clinical, biochemical, and sometimes genetic findings. No single test is diagnostic.

When to Suspect Wilson Disease

• Any unexplained liver disease in patients <40 years
• Neurological symptoms with liver disease
• Psychiatric symptoms with movement disorder
• Family history of Wilson disease
• Fulminant hepatic failure with hemolysis
• Unexplained chronic hepatitis

Diagnostic Tests

Serum Ceruloplasmin

• Low (<20 mg/dL) in 95% of patients
• Can be normal in 5% (especially with hepatic inflammation)
• Can be low in other conditions:
  • Malnutrition
  • Nephrotic syndrome
  • Malabsorption
  • Aceruloplasminemia

24-Hour Urine Copper

• >100 μg/24h suggests Wilson disease
• >40 μg/24h in asymptomatic patients
• Can be elevated in other liver diseases
• Proper collection crucial
• Penicillamine challenge test increases sensitivity

Serum "Free" Copper

• Calculated: Total copper - (3.15 × ceruloplasmin)
• >25 μg/dL suggests Wilson disease
• Useful for monitoring treatment

Slit-Lamp Examination

• Essential in all suspected cases
• Kayser-Fleischer rings nearly universal in neurological Wilson
• May be absent in purely hepatic presentation
• Disappear with effective treatment

Liver Copper Content

• Gold standard: >250 μg/g dry weight
• Normal: <50 μg/g
• Requires adequate sample (>1 cm core)
• Can be patchy distribution
• Elevated in other cholestatic diseases

Imaging Studies

• Brain MRI:
  • "Face of giant panda" sign
  • T2 hyperintensity in basal ganglia
  • Thalamus, brainstem involvement
  • May be normal early
• Liver imaging:
  • Ultrasound: fatty liver, cirrhosis
  • CT/MRI: assess cirrhosis complications

Leipzig Scoring System

Points assigned for various findings:

• 4 points: KF rings + neurological symptoms
• 2 points: KF rings, ceruloplasmin <10, urine copper >2× ULN
• 1 point: Ceruloplasmin 10-20, urine copper 1-2× ULN
• Score ≥4: Diagnosis established
• Score 3: Diagnosis probable
• Score ≤2: Diagnosis unlikely

Genetic Testing

• Confirms diagnosis if mutations found
• Useful for family screening
• Not required for diagnosis
• May miss rare mutations

Family Screening

All first-degree relatives should be screened:

• Physical examination
• Ceruloplasmin level
• 24-hour urine copper
• Liver function tests
• Slit-lamp examination if abnormal tests
• Genetic testing if mutation known

Treatment

Wilson disease is fatal if untreated but responds well to therapy. Treatment must be lifelong and aims to remove excess copper and prevent reaccumulation.

Treatment Phases

1. Initial treatment: Remove excess copper
2. Maintenance therapy: Prevent reaccumulation

Chelation Therapy

D-Penicillamine

• First-line for symptomatic patients
• Dosing:
  • Initial: 250-500 mg/day
  • Increase gradually to 1000-1500 mg/day
  • Divided into 2-4 doses
  • Take on empty stomach
• Monitoring:
  • 24-hour urine copper (increases initially)
  • CBC, urinalysis weekly initially
  • Watch for neurological worsening
• Side effects (30%):
  • Early: fever, rash, lymphadenopathy
  • Late: nephrotoxicity, bone marrow suppression
  • Lupus-like syndrome
  • Elastosis perforans serpiginosa
• Add pyridoxine 25-50 mg/day

Trientine

• Alternative chelator
• Indications:
  • Penicillamine intolerance
  • First-line in some centers
• Dosing:
  • Initial: 750-1500 mg/day
  • Maintenance: 750-1000 mg/day
  • Divided into 2-3 doses
  • Empty stomach
• Advantages:
  • Fewer side effects
  • Less neurological worsening
• Side effects:
  • Gastritis
  • Iron deficiency
  • Rare: pancytopenia

Zinc Therapy

• Mechanism: Blocks intestinal copper absorption
• Indications:
  • Maintenance therapy
  • Presymptomatic patients
  • Pregnancy
• Dosing:
  • Elemental zinc 150 mg/day
  • Divided into 3 doses
  • Separate from food by 1 hour
• Formulations:
  • Zinc acetate (preferred)
  • Zinc sulfate
  • Zinc gluconate
• Side effects:
  • Gastric irritation (common)
  • Take with small protein snack if needed
• Monitoring:
  • 24-hour urine copper <75 μg/day
  • Urine zinc >2000 μg/day

Combination Therapy

• Chelator + zinc during initial treatment
• Separate doses by ≥5 hours
• May improve outcomes
• Transition to zinc monotherapy for maintenance

Treatment of Specific Presentations

Neurological Wilson Disease

• Start with low-dose chelation
• Gradual dose escalation
• 25% experience initial worsening
• Consider trientine or zinc to minimize worsening
• Physical therapy essential

Fulminant Hepatic Failure

• Medical therapy usually ineffective
• Urgent liver transplantation
• Albumin dialysis, plasmapheresis as bridge
• Prognostic score: bilirubin, AST, INR, WBC

Asymptomatic Patients

• Treatment prevents symptoms
• Zinc monotherapy often sufficient
• Regular monitoring essential

Liver Transplantation

Indications:

• Fulminant hepatic failure
• Decompensated cirrhosis failing medical therapy
• Severe neurological deterioration despite treatment

Outcomes:

• Excellent survival (>90% at 5 years)
• Cures metabolic defect
• Neurological symptoms may improve
• No need for continued chelation

Monitoring and Follow-up

Regular monitoring ensures treatment efficacy and detects complications early.

Initial Treatment Phase

• Weekly for first month:
  • Clinical assessment
  • CBC with differential
  • Urinalysis for proteinuria
• Monthly for 6 months:
  • Liver function tests
  • 24-hour urine copper
  • Serum copper and ceruloplasmin
  • Renal function

Maintenance Phase

• Every 3-6 months:
  • Physical examination
  • Neurological assessment
  • Liver tests
  • 24-hour urine copper
  • CBC, renal function
• Annually:
  • Slit-lamp examination
  • Liver ultrasound if cirrhotic
  • Bone density if at risk

Treatment Goals

• Chelation therapy:
  • Urine copper 200-500 μg/day
  • Free serum copper <15 μg/dL
• Zinc therapy:
  • Urine copper <75 μg/day
  • Urine zinc >2000 μg/day

Assessment of Response

• Clinical improvement:
  • Hepatic: 3-6 months
  • Neurological: 6-24 months
  • Psychiatric: Variable
• Laboratory normalization:
  • Transaminases improve first
  • Synthetic function slower
• Kayser-Fleischer rings: Fade over 1-3 years

Non-Adherence Detection

• Rising free copper
• Low 24-hour urine copper
• Clinical deterioration
• Return of KF rings

Dietary Management

Dietary copper restriction plays a supportive role but is not sufficient as sole therapy.

High-Copper Foods to Limit

• Very high (>2 mg/serving):
  • Liver and organ meats
  • Shellfish (oysters, crab, lobster)
  • Chocolate and cocoa
  • Nuts and seeds
  • Mushrooms
• Moderately high (0.5-2 mg/serving):
  • Whole grains
  • Dried fruits
  • Legumes
  • Avocados

Dietary Recommendations

• First 6 months: Avoid high-copper foods
• Maintenance: Moderate restriction sufficient
• Water: Check if >0.1 mg/L copper
  • Run tap 30 seconds before use
  • Avoid copper pipes if possible
  • Consider filtration system
• Cookware: Avoid copper pots and pans

Nutritional Considerations

• Ensure adequate protein intake
• Monitor for zinc-induced copper deficiency
• Iron supplementation if deficient
• Calcium and vitamin D for bone health

Pregnancy Considerations

Women with Wilson disease can have successful pregnancies with careful management.

Pre-Conception Planning

• Optimize treatment before pregnancy
• Genetic counseling
• Partner testing if desired
• Discuss medication adjustments

Treatment During Pregnancy

• Continue treatment throughout pregnancy
• Chelation therapy:
  • Reduce dose by 25-50%
  • D-penicillamine: Risk of cutis laxa in newborn
  • Trientine: Limited data but appears safer
• Zinc therapy:
  • Preferred during pregnancy
  • Maintain standard dosing
  • Monitor closely

Monitoring

• Monthly clinical assessment
• Quarterly copper studies
• Watch for hepatic decompensation
• High-risk obstetric care

Postpartum

• Return to full-dose therapy immediately
• Breastfeeding generally safe
• Monitor infant for copper deficiency if breastfeeding on chelation

Complications

Complications arise from copper toxicity, treatment side effects, or disease progression.

Disease-Related Complications

• Hepatic:
  • Cirrhosis and portal hypertension
  • Hepatocellular carcinoma (rare)
  • Variceal bleeding
  • Ascites
  • Hepatic encephalopathy
• Neurological:
  • Permanent disability if untreated
  • Dysphagia leading to aspiration
  • Falls and fractures
  • Status dystonicus (rare)
• Psychiatric:
  • Severe depression
  • Suicide risk
  • Psychosis
  • Cognitive impairment

Treatment Complications

• Neurological worsening:
  • Occurs in 10-25% initially
  • Usually reversible
  • May take months to improve
• Copper deficiency:
  • From overtreatment
  • Anemia, neutropenia
  • Neuropathy
• Drug toxicity:
  • Penicillamine: Multiple organ systems
  • Trientine: Generally well-tolerated
  • Zinc: Mainly GI upset

Living with Wilson Disease

With proper treatment, most patients lead normal lives. Success requires lifelong commitment to therapy.

Medication Adherence

• Never stop treatment, even if feeling well
• Set reminders for doses
• Use pill organizers
• Keep extra medication for travel
• Understand consequences of non-adherence

Lifestyle Modifications

• Regular medical care:
  • Keep all appointments
  • Complete monitoring tests
  • Report new symptoms promptly
• Physical activity:
  • Regular exercise beneficial
  • Physical therapy for neurological symptoms
  • Occupational therapy as needed
• Mental health:
  • Address depression/anxiety
  • Support groups helpful
  • Family counseling

Education and Work

• Most can pursue normal education
• May need accommodations initially
• Career choice unrestricted if treated
• Inform school/employer about medical needs

Family Planning

• Normal fertility with treatment
• Genetic counseling available
• Children have 0.5% risk if partner not carrier
• Prenatal testing available

Travel Considerations

• Carry medication supply
• Letter from doctor explaining condition
• Research medical facilities at destination
• Maintain dosing schedule across time zones

Support Resources

• Connect with patient organizations
• Online support groups
• Educational materials for family
• Advocacy for insurance coverage

Prognosis

Prognosis depends entirely on early diagnosis and treatment adherence.

With Treatment

• Presymptomatic patients: Normal lifespan expected
• Hepatic presentation:
  • Excellent if pre-cirrhotic
  • Good even with compensated cirrhosis
  • Variable with decompensation
• Neurological presentation:
  • Most improve significantly
  • Complete recovery possible if early
  • Residual symptoms may persist
• Psychiatric presentation:
  • Often complete resolution
  • May need continued psychiatric care

Without Treatment

• Universally fatal
• Hepatic: Death within 2-7 years
• Neurological: Progressive disability, death within 5-15 years

Factors Affecting Prognosis

• Favorable:
  • Early diagnosis
  • Presymptomatic detection
  • Good treatment adherence
  • Mild symptoms at diagnosis
• Unfavorable:
  • Delayed diagnosis
  • Advanced cirrhosis
  • Severe neurological symptoms
  • Poor adherence
  • Fulminant presentation

Long-term Outcomes

• Most patients stabilize within 2 years
• Continued improvement possible for years
• Normal quality of life achievable
• Regular monitoring prevents deterioration

Current Research

Research focuses on improving diagnosis, developing new treatments, and understanding pathophysiology.

Diagnostic Advances

• Novel biomarkers
• Quantitative copper imaging
• Newborn screening feasibility
• Point-of-care testing

Therapeutic Development

• Gene therapy:
  • AAV-mediated ATP7B delivery
  • Phase 1 trials underway
  • Potential one-time cure
• Novel chelators:
  • Improved selectivity
  • Fewer side effects
  • Oral formulations
• Chaperone therapy:
  • Restore mutant protein function
  • Mutation-specific approach

Basic Science

• Copper transport mechanisms
• Genotype-phenotype correlations
• Animal models
• Modifier genes
• Neurodegeneration mechanisms

Clinical Trials

• Bis-choline tetrathiomolybdate (new chelator)
• Gene therapy protocols
• Combination therapy strategies
• Biomarker validation studies

Resources and Support

Patient Organizations

• Wilson Disease Association: Leading patient advocacy group
• Eurowilson: European network
• Wilson Disease Association UK: UK support
• National Organization for Rare Disorders: General rare disease resources

Medical Centers of Excellence

• Yale University (USA)
• University of Michigan (USA)
• King's College Hospital (UK)
• University of Heidelberg (Germany)

Educational Resources

• WilsonDisease.org
• Patient education videos
• Dietary guides
• Treatment tracking apps

Key Questions for Your Doctor

• How severe is my copper accumulation?
• Which organs are affected?
• What treatment is best for me?
• How often do I need monitoring?
• Should my family be tested?
• Can I have children safely?
• Are there clinical trials I could join?
• What happens if I miss doses?